Comparative Pharmacology
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus TRIAD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus TRIAD.
ALMOTRIPTAN MALATE vs TRIAD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; cranial vasoconstriction and inhibition of trigeminal nerve transmission.
Triad is a combination of three antibiotics: amoxicillin, metronidazole, and tetracycline. Amoxicillin inhibits bacterial cell wall synthesis. Metronidazole disrupts bacterial DNA synthesis via reduction to toxic metabolites. Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
12.5 mg orally at onset of migraine; may repeat after 2 hours if headache recurs. Maximum 25 mg/day.
Not applicable. TRIAD is not a recognized drug; no standard dosing exists.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours. In patients with hepatic impairment, half-life may be prolonged (up to 6-7 hours), necessitating dose adjustment.
Terminal t1/2 = 12–15 hours; prolonged to 24–36 hours in hepatic impairment.
Approximately 70% renal excretion (40% unchanged, 30% as metabolites), 30% fecal/biliary elimination.
Renal: 30% unchanged; Biliary/fecal: 70% as metabolites.
Category C
Category C
Antimigraine Agent
Antimigraine Agent